Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 811 to 825 of 1397 results for 0

  1. Good practice guidance – Integrated process statement (PMG12)

    This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

  2. Transcatheter endovascular closure of perimembranous ventricular septal defect (HTG213)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

  3. Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

    Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.

  4. Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)

    Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.

  5. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

  6. Avelumab for treating metastatic Merkel cell carcinoma (TA517)

    Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.

  7. Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease (HTG294)

    Evidence-based recommendations on percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease. This involves using a baloon to widen the artery at the site of the blockage.

  8. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.

  9. Eltrombopag for treating chronic immune thrombocytopenia (TA293)

    Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.

  10. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.

  11. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  12. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA836)

    Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

  13. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

    Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.

  14. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)

    Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.

  15. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.